Oncology Today with Dr Neil Love

Featuring an interview with Prof Dr Sibylle Loibl, including the following topics:
Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)
Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)
Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)
Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)
Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53)
Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44)
Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54)
Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03)

CME information and select publications

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:
Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)
Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)
Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)
Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43)
Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43)
Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15)
Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30)

CME information and select publications

Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics:
Introduction (00:00)
Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40)
Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41)
Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12)
Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35)
Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39)

CME information and select publications

Featuring an interview with Dr Mark Jeng and Dr Joshua K Sabari, including the following topics:
Case: A woman in her late 90s with recurrent HER2-mutant metastatic non-small cell lung cancer (NSCLC) receives third-line zongertinib (0:00)
Case: A woman in her early 60s with multiregimen-recurrent HER2-mutant metastatic NSCLC experiences a response to zongertinib (8:07)
Case: A man in his mid 80s experiences metastatic recurrence after resection of PD-L1-positive, HER2-mutant metastatic NSCLC (17:50)

CME information and select publications

Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:
Introduction: ODAC — April 30, 2026 (00:00)
Adjuvant CDK4/6 Inhibitors (13:03)
Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)
Premenopausal Patients (30:52)
Duration of Adjuvant Endocrine Treatment (38:44)
Genomic Predictors of Chemotherapy Benefit (47:19)
Neoadjuvant Treatment (55:13)

CME information and select publications